Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Oncology
Reference15 articles.
1. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma;Larkin;N Engl J Med,2015
2. Pembrolizumab versus Ipilimumab in Advanced Melanoma;Robert;N Engl J Med,2015
3. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial;Weber;Lancet Oncol,2015
4. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015
5. Management of toxicities of immune checkpoint inhibitors;Spain;Cancer Treat Rev,2016
Cited by 87 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Glucocorticoid efficacy and treatment strategies for drug-induced liver injury: a literature review;Molecular Biology Reports;2024-07-31
2. Hepatobiliary complications of immune checkpoint inhibitors in cancer;Exploration of Targeted Anti-tumor Therapy;2024-07-26
3. Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids;Journal for ImmunoTherapy of Cancer;2024-07
4. Tocilizumab in the treatment of steroid refractory immune-related hepatotoxicity: a case series and review of the literature;Melanoma Research;2024-04-29
5. New advances in the study of PD-1/PD-L1 inhibitors-induced liver injury;International Immunopharmacology;2024-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3